Understanding the molecular link between SPOP gene expression and breast cancer stem cell

Purpose: Breast cancer stem cells are responsible for tumor initiation, abnormal cellular proliferation and metastasis. The activation of breast cancer stem cells is regulated by many genes and the expression of tumor suppressors has a control over it. Speckle-type POZ protein (SPOP) is similar to tumor suppressor that their intact presence inhibits tumor development and any mutation in this gene is re-sponsible for many cancer types. However the exact mechanism of SPOP in controlling cancer stem cells still has not been revealed. Materials and Methods: NOD SCID mouse was used for initiating breast tumor by injecting MDA-MB-231 cell type. The expression of ALDH1 and SPOP are analyzed using Immunohistochemistry and Western blotting. Results: The mice injected with tumor cells de-velop a primary tumor at four weeks and it develops advanced stage of breast cancer at nine weeks. Tumor formation and associated cellular complexity are observed through histological evidence. Also, the expression of ALDH1 shows overexpression pattern as tumor progress to the next level. Interestingly, the authors observed the expression of SPOP shows an abundant expression pattern in the initial stage of breast cancer and noticed its downregulated expression as tumor adverse. Conclusion: The results demonstrate that the highest expression of SPOP had a control over cancer stem cells in the initial stages of breast cancer.

SPOP; ALDH1; MDA-MB-231 cells; Cancer stem cells; Primary tumor.

[1] Chiang K., Zielinska A.E., Shaaban A.M., Sanchez-Bailon M.P., Jar-rold J., Clarke T.L., et al.: “PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Ex-pression”. Cell. Rep., 2017, 21, 3498.

[2] Colditz G.A., Bohlke K.: “Priorities for the primary prevention of breast cancer”. CA. Cancer J.. Clin., 2014, 64, 186.

[3] Gray J.M., Rasanayagam S., Engel C., Rizzo J.: “State of the evi-dence 2017: an update on the connection between breast cancer and the environment”. Environ. Heal., 2017, 16, 94.

[4] Smalley M, Ashworth A.: “Stem cells and breast cancer: a field in transit”. Nat. Rev. Cancer, 2003, 3, 832.

[5] Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., et al.: “Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy”. J. Natl. Cancer. Inst, 2008, 100, 672.

[6] Ablett M.P., O’Brien C.S., Sims A.H., Farnie G., Clarke R.B.: “A differential role for CXCR4 in the regulation of normal versus ma-lignant breast stem cell activity”. Oncotarget, 2014, 5, 599.

[7] Boysen G., Barbieri C.E., Prandi D., Blattner M., Chae S.S., Dahija A., et al.: “SPOP mutation leads to genomic instability in prostate cancer”. Elife, 2015, 16, 4.

[8] Kim M.S., Je E.M., Oh J.E., Yoo N.J., Lee S.H.: “Mutational and expressional analyses of SPOP, a candidate tumor suppressor gene, in prostate, gastric and colorectal cancers”. Apmis 2013, 121, 626.

[9] Jung S.H., Kim M.S., Jung C.K., Park H.C., Kim S.Y., Liu J., et al.: “Mutational burdens and evolutionary ages of thyroid follicular ade-noma are comparable to those of follicular carcinoma”. Oncotarget, 2016, 7, 69638.

[10] Tan Y., Ci Y., Dai X., Wu F., Guo J., Liu D., et al.: “Cullin 3SPOP ubiquitin E3 ligase promotes the poly-ubiquitination and degradation of HDAC6”. Oncotarget, 2017, 8, 47890.

[11] de Beça F.F., Caetano P., Gerhard R., Alvarenga C.A., Gomes M., Paredes J., Schmitt F.: “Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types”. J. Clin. Pathol, 2013, 66, 187.

[12] Fantozzi A., Christofori G.: “Mouse models of breast cancer metas-tasis”. Breast. Cancer. Res, 2006, 8, 212.

[13] Iorns E., Drews-Elger K., Ward T.M., Dean S., Clarke J., Berry D., et al.: “A new mouse model for the study of human breast cancer metastasis”. PLoS One, 2012, 7, e47995.

[14] Li C., Ao J., Fu J., Lee D.F., Xu J., Lonard D., O’Malley B.W.: “Tumor-suppressor role for the SPOP ubiquitin ligase in signal-de-pendent proteolysis of the oncogenic co-activator SRC-3/AIB1”. Oncogene, 2011, 30, 4350.

[15] Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, et al.: “SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K/mTOR and AR signaling”. Cancer. Cell, 2017, 31, 436.

[16] Jin X., Wang J., Gao K., Zhang P., Yao L., Tang Y., et al.: “Dysreg-ulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer”. PLoS. Genet 2017, 13, e1006748.